Does focal heterogeneity affect survival in postoperative ipsilateral multifocal and multicentric breast cancers?

Detalhes bibliográficos
Autor(a) principal: Dal,Fatih
Data de Publicação: 2022
Outros Autores: Ökmen,Hasan, Ulusan,Kivilcim, Çolak,Şükrü, Havare,Semiha Battal, Trabulus,Fadime Didem Can, Ferlengez,Ekrem, Sari,Serkan
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista da Associação Médica Brasileira (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000300405
Resumo: SUMMARY OBJECTIVE: In multicentric/multifocal breast tumors, there may be immunological and histological differences between foci that may affect survival and treatment choice. We aimed to evaluate the effect of focal heterogeneity seen in multicentric/multifocal breast tumors on survival. METHODS: We retrospectively collected and analyzed the clinicopathological data of 89 female patients with multifocal/multicentric breast cancer, whose surgical and medical treatment was completed and who were followed up for 5 years. RESULTS: Of all patients, 29.2% (26/89) were heterogeneous. Heterogeneity of these foci was as follows: histologic heterogeneity of index foci (mix type): 15.7% (14/89), histologic heterogeneity of inter-foci: 7.9% (7/89), and immunohistochemical heterogeneity of inter-foci: 10.1% (9/89). When additional foci were evaluated, oncological therapy was changed for 3 (3.3%) of 89 patients. Heterogeneity does not have a significant (p>0.05) effect on recurrence and survival in multicentric/multifocal breast cancers. Pathological N stage is an independent risk factor for disease-free survival (hazard ratio=2.29, 95% confidence interval=1.39–3.76, p=0.001). CONCLUSIONS: In multifocal/multicentric breast cancers, less than 4% of patients may experience heterogeneity requiring change in the therapeutic decision. However, heterogeneity does not have a significant effect on recurrence and survival in multifocal/multicentric breast cancers. The pathological N stage is an independent risk factor for disease-free survival.
id AMB-1_e7086bbc6b0bd5575e3431bef68b0a7f
oai_identifier_str oai:scielo:S0104-42302022000300405
network_acronym_str AMB-1
network_name_str Revista da Associação Médica Brasileira (Online)
repository_id_str
spelling Does focal heterogeneity affect survival in postoperative ipsilateral multifocal and multicentric breast cancers?Breas cancerMultifocalMulticentricTumor heterogeneitySurvivalSUMMARY OBJECTIVE: In multicentric/multifocal breast tumors, there may be immunological and histological differences between foci that may affect survival and treatment choice. We aimed to evaluate the effect of focal heterogeneity seen in multicentric/multifocal breast tumors on survival. METHODS: We retrospectively collected and analyzed the clinicopathological data of 89 female patients with multifocal/multicentric breast cancer, whose surgical and medical treatment was completed and who were followed up for 5 years. RESULTS: Of all patients, 29.2% (26/89) were heterogeneous. Heterogeneity of these foci was as follows: histologic heterogeneity of index foci (mix type): 15.7% (14/89), histologic heterogeneity of inter-foci: 7.9% (7/89), and immunohistochemical heterogeneity of inter-foci: 10.1% (9/89). When additional foci were evaluated, oncological therapy was changed for 3 (3.3%) of 89 patients. Heterogeneity does not have a significant (p>0.05) effect on recurrence and survival in multicentric/multifocal breast cancers. Pathological N stage is an independent risk factor for disease-free survival (hazard ratio=2.29, 95% confidence interval=1.39–3.76, p=0.001). CONCLUSIONS: In multifocal/multicentric breast cancers, less than 4% of patients may experience heterogeneity requiring change in the therapeutic decision. However, heterogeneity does not have a significant effect on recurrence and survival in multifocal/multicentric breast cancers. The pathological N stage is an independent risk factor for disease-free survival.Associação Médica Brasileira2022-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000300405Revista da Associação Médica Brasileira v.68 n.3 2022reponame:Revista da Associação Médica Brasileira (Online)instname:Associação Médica Brasileira (AMB)instacron:AMB10.1590/1806-9282.20211168info:eu-repo/semantics/openAccessDal,FatihÖkmen,HasanUlusan,KivilcimÇolak,ŞükrüHavare,Semiha BattalTrabulus,Fadime Didem CanFerlengez,EkremSari,Serkaneng2022-09-01T00:00:00Zoai:scielo:S0104-42302022000300405Revistahttps://ramb.amb.org.br/ultimas-edicoes/#https://old.scielo.br/oai/scielo-oai.php||ramb@amb.org.br1806-92820104-4230opendoar:2022-09-01T00:00Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)false
dc.title.none.fl_str_mv Does focal heterogeneity affect survival in postoperative ipsilateral multifocal and multicentric breast cancers?
title Does focal heterogeneity affect survival in postoperative ipsilateral multifocal and multicentric breast cancers?
spellingShingle Does focal heterogeneity affect survival in postoperative ipsilateral multifocal and multicentric breast cancers?
Dal,Fatih
Breas cancer
Multifocal
Multicentric
Tumor heterogeneity
Survival
title_short Does focal heterogeneity affect survival in postoperative ipsilateral multifocal and multicentric breast cancers?
title_full Does focal heterogeneity affect survival in postoperative ipsilateral multifocal and multicentric breast cancers?
title_fullStr Does focal heterogeneity affect survival in postoperative ipsilateral multifocal and multicentric breast cancers?
title_full_unstemmed Does focal heterogeneity affect survival in postoperative ipsilateral multifocal and multicentric breast cancers?
title_sort Does focal heterogeneity affect survival in postoperative ipsilateral multifocal and multicentric breast cancers?
author Dal,Fatih
author_facet Dal,Fatih
Ökmen,Hasan
Ulusan,Kivilcim
Çolak,Şükrü
Havare,Semiha Battal
Trabulus,Fadime Didem Can
Ferlengez,Ekrem
Sari,Serkan
author_role author
author2 Ökmen,Hasan
Ulusan,Kivilcim
Çolak,Şükrü
Havare,Semiha Battal
Trabulus,Fadime Didem Can
Ferlengez,Ekrem
Sari,Serkan
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Dal,Fatih
Ökmen,Hasan
Ulusan,Kivilcim
Çolak,Şükrü
Havare,Semiha Battal
Trabulus,Fadime Didem Can
Ferlengez,Ekrem
Sari,Serkan
dc.subject.por.fl_str_mv Breas cancer
Multifocal
Multicentric
Tumor heterogeneity
Survival
topic Breas cancer
Multifocal
Multicentric
Tumor heterogeneity
Survival
description SUMMARY OBJECTIVE: In multicentric/multifocal breast tumors, there may be immunological and histological differences between foci that may affect survival and treatment choice. We aimed to evaluate the effect of focal heterogeneity seen in multicentric/multifocal breast tumors on survival. METHODS: We retrospectively collected and analyzed the clinicopathological data of 89 female patients with multifocal/multicentric breast cancer, whose surgical and medical treatment was completed and who were followed up for 5 years. RESULTS: Of all patients, 29.2% (26/89) were heterogeneous. Heterogeneity of these foci was as follows: histologic heterogeneity of index foci (mix type): 15.7% (14/89), histologic heterogeneity of inter-foci: 7.9% (7/89), and immunohistochemical heterogeneity of inter-foci: 10.1% (9/89). When additional foci were evaluated, oncological therapy was changed for 3 (3.3%) of 89 patients. Heterogeneity does not have a significant (p>0.05) effect on recurrence and survival in multicentric/multifocal breast cancers. Pathological N stage is an independent risk factor for disease-free survival (hazard ratio=2.29, 95% confidence interval=1.39–3.76, p=0.001). CONCLUSIONS: In multifocal/multicentric breast cancers, less than 4% of patients may experience heterogeneity requiring change in the therapeutic decision. However, heterogeneity does not have a significant effect on recurrence and survival in multifocal/multicentric breast cancers. The pathological N stage is an independent risk factor for disease-free survival.
publishDate 2022
dc.date.none.fl_str_mv 2022-03-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000300405
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000300405
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/1806-9282.20211168
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Médica Brasileira
publisher.none.fl_str_mv Associação Médica Brasileira
dc.source.none.fl_str_mv Revista da Associação Médica Brasileira v.68 n.3 2022
reponame:Revista da Associação Médica Brasileira (Online)
instname:Associação Médica Brasileira (AMB)
instacron:AMB
instname_str Associação Médica Brasileira (AMB)
instacron_str AMB
institution AMB
reponame_str Revista da Associação Médica Brasileira (Online)
collection Revista da Associação Médica Brasileira (Online)
repository.name.fl_str_mv Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)
repository.mail.fl_str_mv ||ramb@amb.org.br
_version_ 1754212837388976128